BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 32935235)

  • 1. Sustained absorption of delamanid from lipid-based formulations as a path to reduced frequency of administration.
    Ramirez G; Pham AC; Clulow AJ; Salim M; Hawley A; Boyd BJ
    Drug Deliv Transl Res; 2021 Jun; 11(3):1236-1244. PubMed ID: 32935235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phytantriol and glyceryl monooleate cubic liquid crystalline phases as sustained-release oral drug delivery systems for poorly water-soluble drugs II. In-vivo evaluation.
    Nguyen TH; Hanley T; Porter CJ; Larson I; Boyd BJ
    J Pharm Pharmacol; 2010 Jul; 62(7):856-65. PubMed ID: 20636873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanostructured reverse hexagonal liquid crystals sustain plasma concentrations for a poorly water-soluble drug after oral administration.
    Nguyen TH; Hanley T; Porter CJ; Boyd BJ
    Drug Deliv Transl Res; 2011 Dec; 1(6):429-38. PubMed ID: 25786363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Vivo Formation of Cubic Phase in Situ after Oral Administration of Cubic Phase Precursor Formulation Provides Long Duration Gastric Retention and Absorption for Poorly Water-Soluble Drugs.
    Pham AC; Hong L; Montagnat O; Nowell CJ; Nguyen TH; Boyd BJ
    Mol Pharm; 2016 Jan; 13(1):280-6. PubMed ID: 26567591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanostructured liquid crystalline particles provide long duration sustained-release effect for a poorly water soluble drug after oral administration.
    Nguyen TH; Hanley T; Porter CJ; Boyd BJ
    J Control Release; 2011 Jul; 153(2):180-6. PubMed ID: 21497623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Examining the gastrointestinal transit of lipid-based liquid crystalline systems using whole-animal imaging.
    Pham AC; Nguyen TH; Nowell CJ; Graham B; Boyd BJ
    Drug Deliv Transl Res; 2015 Dec; 5(6):566-74. PubMed ID: 26328930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phytantriol and glyceryl monooleate cubic liquid crystalline phases as sustained-release oral drug delivery systems for poorly water soluble drugs I. Phase behaviour in physiologically-relevant media.
    Nguyen TH; Hanley T; Porter CJ; Larson I; Boyd BJ
    J Pharm Pharmacol; 2010 Jul; 62(7):844-55. PubMed ID: 20636872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A lipid-based liquid crystalline matrix that provides sustained release and enhanced oral bioavailability for a model poorly water soluble drug in rats.
    Boyd BJ; Khoo SM; Whittaker DV; Davey G; Porter CJ
    Int J Pharm; 2007 Aug; 340(1-2):52-60. PubMed ID: 17467935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Revisiting dispersible milk-drug tablets as a solid lipid formulation in the context of digestion.
    Binte Abu Bakar SY; Salim M; Clulow AJ; Hawley A; Boyd BJ
    Int J Pharm; 2019 Jan; 554():179-189. PubMed ID: 30391337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solubilisation behaviour of poorly water-soluble drugs during digestion of solid SMEDDS.
    Vithani K; Hawley A; Jannin V; Pouton C; Boyd BJ
    Eur J Pharm Biopharm; 2018 Sep; 130():236-246. PubMed ID: 29981444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transformation of poorly water-soluble drugs into lipophilic ionic liquids enhances oral drug exposure from lipid based formulations.
    Sahbaz Y; Williams HD; Nguyen TH; Saunders J; Ford L; Charman SA; Scammells PJ; Porter CJ
    Mol Pharm; 2015 Jun; 12(6):1980-91. PubMed ID: 25905624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Digestion is a critical element for absorption of cinnarizine from supersaturated lipid-based type I formulations.
    Paulus F; Bauer-Brandl A; Stappaerts J; Holm R
    Eur J Pharm Sci; 2024 Jan; 192():106634. PubMed ID: 37951315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formulation and development of bicontinuous nanostructured liquid crystalline particles of efavirenz.
    Avachat AM; Parpani SS
    Colloids Surf B Biointerfaces; 2015 Feb; 126():87-97. PubMed ID: 25543986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absorption, distribution and excretion of the anti-tuberculosis drug delamanid in rats: Extensive tissue distribution suggests potential therapeutic value for extrapulmonary tuberculosis.
    Shibata M; Shimokawa Y; Sasahara K; Yoda N; Sasabe H; Suzuki M; Umehara K
    Biopharm Drug Dispos; 2017 May; 38(4):301-312. PubMed ID: 28092695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solution or suspension - Does it matter for lipid based systems? In vivo studies of chase dosing lipid vehicles with aqueous suspensions of a poorly soluble drug.
    Larsen AT; Holm R; Müllertz A
    Eur J Pharm Biopharm; 2017 Aug; 117():308-314. PubMed ID: 28465239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of lipid digestion on the fate of orally administered drug delivery vehicles.
    Boyd BJ; Clulow AJ
    Biochem Soc Trans; 2021 Aug; 49(4):1749-1761. PubMed ID: 34431506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 'Stealth' lipid-based formulations: poly(ethylene glycol)-mediated digestion inhibition improves oral bioavailability of a model poorly water soluble drug.
    Feeney OM; Williams HD; Pouton CW; Porter CJ
    J Control Release; 2014 Oct; 192():219-27. PubMed ID: 25058571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastric pre-processing is an important determinant of the ability of medium-chain lipid solution formulations to enhance oral bioavailability in rats.
    Lee KW; Porter CJ; Boyd BJ
    J Pharm Sci; 2013 Nov; 102(11):3957-65. PubMed ID: 23983139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Lipid Digestion and Drug Permeation/Re-Dissolution on Absorption of Orally Administered Ritonavir as Different Lipid-Based Formulations.
    Tanaka Y; Doi H; Katano T; Kasaoka S
    Eur J Pharm Sci; 2021 Feb; 157():105604. PubMed ID: 33098990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Digestion of Lipid-Based Formulations Not Only Mediates Changes to Absorption of Poorly Soluble Drugs Due to Differences in Solubilization But Also Reflects Changes to Thermodynamic Activity and Permeability.
    Tanaka Y; Nguyen TH; Suys EJA; Porter CJH
    Mol Pharm; 2021 Apr; 18(4):1768-1778. PubMed ID: 33729806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.